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Panel: Research in context 
Evidence before this study 
 This study was designed on the basis of evidence collected from the clinical development 
of semaglutide, including in vitro receptor studies, carcinogenicity studies, pre- and 
postnatal development toxicity studies, phase 1 single-dose and multi-dose 
pharmacokinetics/pharmacodynamics studies, and a phase 2 dose-finding trial. A 
number of long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) with 
pharmacokinetic properties suitable for once-weekly dosing have been approved for the 
treatment of type 2 diabetes. The currently available products include albiglutide, 
exenatide extended release and dulaglutide. Biochemical methods of protraction differ 
and it is currently unknown if the molecular properties of long-acting GLP-1RAs will have 
differential influences on efficacy or safety parameters. The authors note there is a risk 
of bias in this literature search, in that mainly positive results may have been publicly 
reported for compounds with therapeutic implications. 
Added value of this study 
 Semaglutide is a novel once-weekly GLP-1RA. This study demonstrates that semaglutide 
combines a high degree of glycaemic control with weight loss, without an increased risk 
of hypoglycaemia. The safety profile of semaglutide appears to be similar to currently 
available GLP-1RAs, consisting primarily of gastrointestinal events. 
Implications of all the available evidence  
 Semaglutide appears to be a promising treatment for patients with type 2 diabetes. 
Compared with other currently available once-weekly GLP-1RAs, semaglutide has a low 
molecular weight and a distinctive method of protraction based on its affinity to albumin. 
Early results indicate significant improvements in glycaemic control in patients with type 
2 diabetes. Indirect comparison of data from this study with other similar GLP-1RA 
monotherapy trials indicate that the improvements in glycaemic control are at least 
comparable. The extent of weight loss observed thus far with semaglutide is greater 
than has been reported for other GLP-1RAs. However, head-to-head trials are needed to 
draw firm conclusions on the relative efficacy of semaglutide and other GLP-1RAs. The 
SUSTAIN 2–5 trials assessed the efficacy and safety of once weekly s.c. semaglutide 
versus widely used active comparators, sitagliptin, exenatide extended release, insulin 
glargine and as add-on to insulin. Furthermore, the long-term effects of semaglutide on 
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efficacy, safety and cardiovascular risk were assessed in the SUSTAIN 6 trial; a 
dedicated cardiovascular outcomes trial in adults with type 2 diabetes at high risk of 
cardiovascular disease. This comprehensive clinical trial programme will establish the 
role for semaglutide as part of the diabetes treatment armamentarium.   
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Summary 
Background 
Despite a broad range of pharmacological options for the treatment of type 2 diabetes, 
optimal glycaemic control remains challenging for many patients and new therapies remain 
necessary. Semaglutide is a glucagon-like peptide-1 (GLP-1) analogue in phase 3 
development for type 2 diabetes. The objectives of this trial were to evaluate the efficacy, 
safety and tolerability of semaglutide monotherapy compared with placebo, in treatment-
naïve subjects with type 2 diabetes who had insufficient glycaemic control on diet and 
exercise alone. 
Methods 
SUSTAIN 1 (NCT02054897) was a double-blind, randomised, placebo-controlled phase 3a 
trial. Treatment-naïve participants aged ≥18 years, diagnosed with type 2 diabetes and with 
a baseline HbA1c of 7·0–10·0% were recruited and randomised 2:2:1:1 to receive once-
weekly subcutaneous semaglutide 0·5 mg, semaglutide 1·0 mg, or volume-matched placebo 
for 30 weeks. The primary endpoint was change in mean HbA1c from baseline to week 30. 
The confirmatory secondary endpoint was change in mean body weight from baseline to 
week 30. 
Findings 
Subjects were recruited between 3 February 2014 and 21 August 2014. A total of 388 
adults were randomised. From a mean baseline HbA1c of 8·1%, 0·5 mg and 1·0 mg 
semaglutide achieved superior reductions of 1·5% (estimated treatment difference vs 
placebo [ETD] –1·43%; 95% confidence interval [CI] –1·71, –1·15]; p<0·0001) and 1·6% 
(ETD –1·53%; 95% CI –1·81, –1·25; p<0·0001) respectively, versus no change for placebo. 
From a mean baseline of 91·9 kg, 0·5 mg and 1·0 mg semaglutide achieved superior weight 
loss of 3·7 kg and 4·5 kg, respectively, versus 1·0 kg for placebo (p<0·0001). Drug 
discontinuation rates due to adverse events were 6% and 5% for 0·5 mg and 1·0 mg 
semaglutide, compared with 2% for placebo.  
Interpretation 
Semaglutide was associated with superior improvements in HbA1c and body weight, and 
demonstrated a similar safety profile to currently available GLP-1RAs, representing a 
promising treatment option for patients with type 2 diabetes. 
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Funding: Novo Nordisk A/S, Denmark.  
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Introduction 
Type 2 diabetes is a complex disorder that requires individualised treatment strategies. In 
addition to diet and lifestyle changes, pharmacotherapy is usually required.1 A range of 
therapies are now available for treatment of type 2 diabetes, including orally administered 
and injectable options.1 Guidelines recommend avoidance of both hypoglycaemia and weight 
gain as important therapeutic considerations in selecting treatment and individualising 
treatment goals.1,2 
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) stimulate insulin secretion and inhibit 
the release of glucagon in a glucose-dependent manner, which results in improved blood 
glucose levels combined with a relatively low risk of hypoglycaemia.3 Unlike many other 
therapies for type 2 diabetes, GLP-1RAs have been shown to reduce body weight,4 as a 
consequence of reduced appetite and energy intake,5 as well as to modify the perception of 
food.6 
Short-acting GLP-1RAs, requiring dosing once or twice daily, were the first to be developed. 
Recent efforts have focused on developing GLP-1RAs that require less frequent dosing, with 
a view to reducing treatment burden and improving patient adherence.7 Currently three 
GLP-1RAs are available that can be administered once-weekly; exenatide extended release, 
albiglutide, and dulaglutide.4  
Semaglutide is a GLP-1 analogue currently in development for the treatment of type 2 
diabetes. It has 94% structural homology to native GLP-1, and is based on the same 
technology as liraglutide.8 Structural modifications make semaglutide more resistant to 
degradation by dipeptidyl peptidase-4 (DPP-4) and improve binding to albumin.8 These 
modifications result in a half-life of approximately one week, making semaglutide 
appropriate for once-weekly subcutaneous (s.c.) administration.8 Semaglutide has a low 
molecular weight, making it likely to reach the brain in a similar manner as described for 
liraglutide.9 
This article reports the findings of a phase 3a trial, SUSTAIN 1, which evaluated 
once-weekly s.c. semaglutide at doses of 0·5 mg and 1·0 mg. The objectives of the trial 
were to evaluate the efficacy, safety and tolerability of semaglutide monotherapy compared 
with placebo, in treatment-naïve subjects with type 2 diabetes who had insufficient 
glycaemic control on diet and exercise alone.  
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Methods 
Study design  
This was a phase 3a, randomised, double-blind, parallel-group, multinational, multicentre 
trial [SUSTAIN 1; ClinicalTrials.gov registration NCT02054897]. Participating sites were 
located in Canada, Italy, Japan, Mexico, Russia, South Africa, UK, and USA. The trial was 
conducted in compliance with the International Conference on Harmonisation Good Clinical 
Practice guidelines and the Declaration of Helsinki.  
Participants  
Patients were ≥18 years of age, had received a diagnosis of type 2 diabetes, and had been 
treated with diet and exercise alone for ≥30 days before screening when enrolled. Eligible 
subjects had HbA1c 7·0–10·0% (53–86 mmol/mol). Key exclusion criteria included treatment 
with glucose-lowering agents in the 90 days prior to screening (except for short-term 
treatment of ≤7 days with insulin), history of chronic or idiopathic acute pancreatitis, 
personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 
syndrome type 2, impaired renal function (estimated glomerular filtration rate,  
eGFR <30 ml/min/1·73 m2), screening calcitonin values ≥50 ng/L (pg/mL), heart failure 
(New York Heart Association class IV), or any acute coronary or cerebrovascular events in 
the 90 days prior to randomisation. Full eligibility criteria are included in Supplementary 
Table 1. Written informed consent was obtained from all participants before commencement 
of any study-related activities. 
Randomisation and masking 
Subjects were randomly assigned, using an interactive voice/web response system, with a 
2:2:1:1 ratio to receive once-weekly s.c. semaglutide (0·5 mg or 1·0 mg) or once-weekly 
volume-matched placebo, ensuring blinding within dose. Both semaglutide placebo and 
active drug were provided in PDS290 pen-injectors and were identical with regards to 
appearance, taste and smell, and equal volume of placebo and active drug were 
administered within each dose-level. The investigators, subjects and sponsor were blinded 
throughout the trial. 
Procedures 
Following a two-week screening period, subjects received s.c. semaglutide 0·5 mg or 1·0 
mg or volume-matched placebo (0·5 mg or 1·0 mg) once-weekly for 30 weeks, followed by 
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a 5-week follow-up period (Supplementary Figure 1). The trial implemented complete 
follow-up on all subjects, including those who discontinued treatment prematurely. All 
subjects in the semaglutide arms followed a fixed-dose escalation regimen, with a 
corresponding volume-matched escalation in the placebo arms. In the semaglutide 0·5 mg 
arm, the maintenance dose was reached after 4 weeks of 0·25 mg semaglutide once-
weekly. In the semaglutide 1·0 mg arm, the maintenance dose was reached after 4 weeks 
of 0·25 mg semaglutide, followed by 4 weeks of 0·5 mg semaglutide. All doses were 
administered using 1·5 mL prefilled PDS290 pen-injectors. Injections could be administered 
in the thigh, abdomen or upper arm, at any time of day and irrespective of meals, provided 
they were on the same day of the week. Subjects were encouraged to inject in the same 
area throughout the trial as data on semaglutide concentration were collected for future 
population pharmacokinetic analyses to show an equivalence between injection sites. 
Subjects with unacceptable hyperglycaemia were to be offered metformin (first choice) or 
other antidiabetic medications (not GLP-1RA or DPP-4 inhibitors) as add-on to their 
randomised treatment (rescue medication) at the discretion of the investigator, in 
accordance with American Diabetes Association (ADA)/European Association for the Study of 
Diabetes (EASD) treatment guidelines.1   
Outcomes 
The primary endpoint was the change in HbA1c levels from baseline to week 30, assessed at 
a central laboratory. The confirmatory secondary endpoint was the change in body weight 
from baseline to week 30. Other secondary efficacy endpoints included: proportion of 
subjects who achieved HbA1c <7·0% (53 mmol/mol) or HbA1c ≤6·5% (48 mmol/mol) by end 
of treatment; a composite endpoint of HbA1c <7·0% with no severe or blood glucose (BG)-
confirmed hypoglycaemia (defined as severe according to the ADA classification10 or 
confirmed by a BG value <3·1 mmol/L [56 mg/dL] with symptoms consistent with 
hypoglycaemia) and no weight gain; change from baseline to week 30 in fasting plasma 
glucose (FPG); self-measured plasma glucose (SMPG) 7-point profiles and prandial 
increments (over all meals); laboratory measurements associated with -cell function and 
glycaemic control (insulin, c-peptide, pro-insulin, glucagon, proinsulin/insulin ratio, and 
homeostasis model assessment of -cell function [HOMA-B] and insulin resistance [HOMA-
IR], all fasting); proportion of subjects who achieved ≥5% and ≥10% weight-loss from 
baseline to week 30; body-mass index (BMI); waist circumference; fasting blood lipids; and 
systolic and diastolic blood pressure.  
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Safety endpoints included the number of treatment-emergent adverse events (AEs) and the 
number of severe or BG-confirmed symptomatic hypoglycaemic episodes during exposure, 
and pulse rate. Other safety measurements were change in laboratory parameters 
(haematology, biochemistry, calcitonin, urinalysis, and urinary albumin-to-creatinine ratio) 
and examinations (ECG and physical examination) at week 30, the occurrence and level of 
anti-semaglutide antibodies, and semaglutide pharmacokinetics (to be included in a future 
population pharmacokinetic analyses across semaglutide phase 3a trials). 
According to US Food and Drug Administration (FDA) requirements, and in an independent 
and blinded manner, an external event adjudication committee (EAC) validated predefined 
events (Supplementary Table 2).  
Statistical analysis 
The two placebo arms were pooled for the efficacy and safety evaluations. The trial was 
designed with 80% power to establish superiority jointly for both doses of semaglutide 
versus pooled placebo (hereafter referred to as placebo) for both HbA1c and body weight at 
week 30 with a one-sided alpha of 2·5%, assuming treatment differences versus placebo of 
0·45% and 2·25 kg, respectively, for each semaglutide dose level and standard deviations 
(SD) of 1·1% and 4·0 kg, respectively. The type-I error probability was controlled at 2·5% 
(one-sided) across the four confirmatory superior hypotheses in a hierarchical testing 
strategy. HbA1c superiority versus placebo was tested first, starting with semaglutide 1·0 mg 
followed by 0·5 mg, followed by body weight superiority versus placebo in the same dose 
order (supplementary material).  
The evaluation of efficacy was based on a modified intention to treat analysis, comprising all 
randomised subjects who were exposed to at least one dose of trial product; the evaluation 
used data collected before initiation of any rescue medication or before premature 
treatment discontinuation. Safety was evaluated based on the same set of subjects. For the 
safety evaluation, only data collected before premature treatment discontinuation with an 
ascertainment window of 42 days were used to identify treatment-emergent AEs. 
Supportive analyses using all data collected during the trial were performed for both efficacy 
and safety. 
Analysis methods for HbA1c and body weight and other continuous endpoints assessed over 
time included a mixed model for repeated measurements (MMRM), with factors for 
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treatment, country and baseline value, all nested within visits. All p-values are two-sided of 
the null hypothesis of no treatment difference. 
The robustness of the analyses of HbA1c and body weight was assessed by handling missing 
data in various ways in analyses, including a placebo-based multiple imputation model 
where missing data points were imputed as if the subject was treated with placebo. 
Sensitivity analyses also included an MMRM analysis on the FAS population using all data, 
regardless of whether obtained while the subjects had discontinued trial product and/or 
whether the subject had been administered rescue medication (supplementary materials).  
 
Role of the funding source 
The sponsor participated in discussions regarding study design and protocol development, 
and provided logistical support during the trial. The sponsor obtained the data, which were 
assessed jointly by the authors and the sponsor. The authors interpreted the data, and 
wrote the report together with medical writing services provided by the sponsor. The 
corresponding author had full access to all data and had final responsibility for the decision 
to submit for publication. 
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Results 
Subjects were recruited between 3 February 2014 and 21 August 2014. In total, 388 
subjects were randomised and 387 exposed to trial medication (Figure 1). The proportion of 
subjects administered rescue medication was 5% with each of semaglutide 0·5 mg and 1·0 
mg, compared with 21% with placebo. The proportion of subjects discontinuing treatment 
prematurely was 13% with semaglutide 0·5 mg, 12% with semaglutide 1·0 mg, and 11% 
with placebo. The main reason for premature treatment discontinuation was AEs (Figure 1). 
Baseline characteristics were similar between the three groups (Table 1) in regard to mean 
diabetes duration, HbA1c, BMI and eGFR. Mean body weight was higher in the semaglutide 
1·0 mg group (96·9 kg [range), compared with the semaglutide 0·5 mg (89·8 kg) and 
placebo (89·1 kg) groups. There was also a higher percentage of males in the semaglutide 
1·0 mg group (61·5%), compared with the semaglutide 0·5 mg (46·9%) and placebo 
(54·3%) groups. 
Mean HbA1c (baseline 8·1%, standard deviation [SD] 0·85) decreased at a similar rate over 
time in both semaglutide groups (Figure 2A and Supplementary Figure 2A). At week 30, 
HbA1c was significantly decreased with semaglutide 0·5 mg and 1·0 mg by 1·5% and 1·6%, 
respectively, versus <0·1% in the placebo group. The estimated treatment difference (ETD) 
versus placebo [95% confidence interval] was –1·43% [–1·71; –1·15] and –1·53% [–1·81; 
–1·25], respectively; p<0·0001 for both (Figure 2B, Table 2). HbA1c <7·0% was achieved by 
74% and 72% of 0·5 mg and 1·0 mg semaglutide-treated subjects, respectively, versus 
25% in the placebo group (p<0·0001 for both; Table 2). This target was achieved without 
severe or BG-confirmed hypoglycaemia and without weight gain in 66% and 65% of 
subjects in the 0·5 mg and 1·0 mg semaglutide groups, respectively, compared with 19% in 
the placebo group (Table 2). HbA1c ≤6·5% was achieved by 59% and 60% of 0·5 mg and 
1·0 mg semaglutide-treated subjects, respectively, versus 13% in the placebo group 
(p<0·0001 for both; Table 2).   
At week 30, mean FPG was significantly reduced with semaglutide 0·5 mg and 1·0 mg by 
2·5 mmol/L and 2·3 mmol/L, respectively, versus 0·6 mmol/L with placebo (ETD –1·96 
mmol/L and –1·79 mmol/L; p<0·0001 for both; Table 2). Mean 7-point SMPG was 
significantly reduced with semaglutide 0·5 mg and 1·0 mg, compared with placebo (ETD –
1·68 mmol/L and –1·99 mmol/L; p<0·0001 for both; Table 2). The mean 7-point SMPG 
post-meal increment was significantly reduced with semaglutide 1·0 mg (ETD –0·74 mmol/L 
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p=0·0014), but the reduction in the semaglutide 0·5 mg group was not significant (ETD –
0·41 mmol/L; p=0·08; Table 2). 
Proinsulin and proinsulin/insulin ratio were significantly reduced, and c-peptide and HOMA-B 
were significantly increased, with both doses of semaglutide versus placebo. HOMA-IR was 
significantly reduced with semaglutide 1·0 mg compared with placebo, but this decrease 
was not significantly greater for semaglutide 0·5 mg versus placebo. No significant changes 
in fasting insulin or plasma glucagon levels were observed (Supplementary Table 3).  
At week 30, body weight was significantly decreased with semaglutide 0·5 mg and 1·0 mg 
by 3·7 kg and 4·5 kg, respectively, versus 1·0 kg in the placebo group (ETD –2·75 kg and –
3·56 kg; p<0·0001 for both; Figure 2D, Table 2). A similar pattern of weight change over 
time was observed in both semaglutide groups (Figure 3C and Supplementary Figure 2B). A 
body weight reduction of ≥5% was achieved by 37% and 45% of 0·5 mg and 1·0 mg 
semaglutide-treated subjects, respectively, versus 7% in the placebo group (p<0·0001 for 
both; Table 2). A body weight reduction of ≥10% was achieved by 8% and 13% of 0·5 mg 
and 1·0 mg semaglutide-treated subjects, respectively, versus 2% in the placebo group 
(p=0·0363 for 0·5 mg, p=0·0018 for 1·0 mg; Table 2). 
BMI and waist circumference were reduced with both doses of semaglutide compared with 
placebo (Table 2). Total cholesterol, LDL-cholesterol and FFA were significantly reduced with 
semaglutide 1·0 mg, compared with placebo. No significant difference in HDL-cholesterol, 
triglycerides and VLDL-cholesterol was observed between semaglutide 0·5 mg, 1·0 mg and 
placebo arms (Supplementary Table 3). Changes in blood pressure were comparable 
between the semaglutide 0·5 mg, 1·0 mg and placebo groups (Table 2).  
The proportion of subjects reporting any AEs was higher with semaglutide 0·5 mg versus 
placebo, while serious AEs (SAEs) were broadly similar between all groups: 64·1%, 56·2% 
and 53·5% of subjects reported AEs with semaglutide 0·5 mg, 1·0 mg and placebo, and 
5·5%, 5·4% and 3·9% reported SAEs, respectively (Table 3; Supplementary Table 4). No 
deaths were reported in any of the groups. The majority of AEs reported were of mild or 
moderate severity (Table 3). The proportion of subjects prematurely discontinuing 
treatment due to AEs was 6·3% for semaglutide 0·5 mg, 5·4% for semaglutide 1·0 mg and 
2·3% for placebo (Supplementary Figure 3).  
The most frequent AEs in the semaglutide groups were gastrointestinal (GI) AEs, and these 
were also responsible for the majority of AEs leading to premature treatment 
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discontinuation (Table 3). In subjects receiving semaglutide 0·5 and 1·0 mg, 20·3% and 
23·8% reported nausea, respectively, versus 7·8% in the placebo group. The rate of nausea 
was observed to decrease over time (Supplementary Figure 3). Vomiting was reported by 
3·9% and 6·9% of subjects in the semaglutide 0·5 and 1·0 mg groups respectively, 
compared with 1·6% in the placebo group. In subjects receiving semaglutide 0·5 and 1·0 
mg, 12·5% and 10·8% reported diarrhoea, respectively, versus 2·3% in the placebo group. 
The majority of GI AEs were mild to moderate (Table 3). 
No episodes of severe or BG-symptomatic confirmed hypoglycaemia were reported in either 
semaglutide group; three events were reported in two subjects (1·6%) in the placebo 
group. All three events occurred after first dose of rescue medication. 
No episodes of pancreatitis were reported in the trial. Lipase significantly increased by 18% 
with semaglutide 0.5 mg and 22% with semaglutide 1.0 mg, compared with a 6% decrease 
with placebo. Corresponding changes for amylase were 11%, 16% and 0%, respectively 
(Supplementary Figure 5). A total of four cases of cholelithiasis were reported: three in 
subjects receiving semaglutide 0·5 mg and one in a subject receiving semaglutide 1·0 mg. 
In one of the subjects receiving semaglutide 0·5 mg, this was categorised as an SAE. No 
cases of cholelithiasis were reported in the placebo arm (Table 3). 
The pulse rate increased significantly with both doses of semaglutide by 2·4 bpm, compared 
with a 0·5 bpm decrease with placebo by week 30 (Table 2). EAC-confirmed neoplasms 
were reported by five subjects treated with semaglutide 0·5 mg, four treated with 
semaglutide 1·0 mg and none in the placebo arm. These neoplasms included four malignant 
cases. Single cases of squamous cell carcinoma of skin and breast cancer were confirmed in 
the semaglutide 0·5 mg group, and single cases of basal cell carcinoma and prostate cancer 
were confirmed in the semaglutide 1·0 mg treatment group. There were no cases of 
pancreatic cancer reported (Table 3). Calcitonin levels in both semaglutide arms were 
consistently low and comparable to placebo, and no C-cell abnormalities were observed. 
A total of 11 subjects developed anti-semaglutide antibodies; none were observed to exhibit 
in vitro neutralising effects on semaglutide or endogenous GLP-1.  
There were no clinically relevant changes in other safety laboratory assessments, physical 
examination or electrocardiograms.  
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Discussion 
In this multicentre, randomised controlled phase 3a trial, both doses of once-weekly 
semaglutide (0·5 mg and 1·0 mg) significantly improved glycaemic control in treatment-
naïve patients with type 2 diabetes, compared with placebo. Nearly three-quarters of 
subjects in the semaglutide groups reached the ADA recommended HbA1c target of 
<7·0%,11 and almost 60% achieved the more stringent American Association of Clinical 
Endocrinologists (AACE) / National Institute for Health and Care Excellence (NICE) target of 
6·5%.2,12 These findings are consistent with observations in an earlier 12-week dose-finding 
study for semaglutide in 415 subjects with type 2 diabetes treated with diet and exercise, 
with or without a stable metformin regimen, where up to 81% of the participants on 
semaglutide 0·1–1·6 mg achieved an HbA1c level of <7·0% (up to 63% for the ≤6·5% 
target).13  
As a dose response was evident in the dose finding study, it was surprising that there was 
no apparent dose-related difference in glycaemic control with semaglutide in this study. 
However, although both doses produced similar mean HbA1c reductions from baseline, the 
decrease in HbA1c was consistently more pronounced in the 1·0 mg semaglutide arm than in 
the 0·5 mg semaglutide arm in all prespecified sensitivity analyses (supplementary figure 
4). A possible explanation could be that the low mean HbA1c achieved by the end of 
treatment, and the high percentage of subjects achieving HbA1c levels of less than 7·0%, 
may have reduced the visibility of a dose-dependent treatment difference in this treatment-
naïve type 2 diabetes population. Furthermore, because the sample size was relatively 
small, the dose-response effect may have been skewed due to 13 subjects who had 
undetectable plasma semaglutide levels throughout the trial, indicating that they had not 
routinely administered the drug. Ten of these subjects were randomised to the 1·0 mg 
semaglutide arm and several had an increase in HbA1c, thereby attenuating the mean HbA1c 
reduction in the 1·0 mg arm. In contrast to HbA1c, weight loss with semaglutide 1·0 mg was 
numerically higher than for semaglutide 0·5 mg. However, GLP-1RA effects on glycaemic 
control and body weight appear to be independent,14 with glycaemic control primarily 
mediated by pancreatic GLP-1 receptors and weight loss by GLP-1 receptors in the brain.15-
17 This supports the proposal that glycaemic effects show different dose-response 
relationships than body weight. 
In this study, both doses of semaglutide led to significant weight loss, compared with 
placebo. This is a particularly relevant finding, because many current treatments for 
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diabetes are either weight-neutral or associated with weight gain. 18-20 Current treatment 
guidelines from ADA/EASD and AACE stress the importance of avoiding weight gain and 
minimising the risk of treatment-emergent hypoglycaemia while managing patients with 
type 2 diabetes. Weight gain and obesity are associated with an increase in the risk of 
cardiovascular complications21 and other comorbidities,22 as well as a reduction in quality of 
life.23 Furthermore, weight gain may contribute to patient frustration and lack of motivation, 
and lead to reduced compliance with medication.24 Studies also suggest that individuals with 
type 2 diabetes are reluctant to begin treatments associated with an increased risk of 
weight gain.1,25 Even the perception that regular use of diabetes therapy would result in 
weight gain is associated with a reduced adherence to treatment in individuals with type 2 
diabetes.25 
Although populations and trial durations may have varied, indirect comparison of the 
findings from this trial with those from similar monotherapy trials with other GLP-1RAs 
indicate that the improvements in glycaemic control and body weight are at least 
comparable – and potentially greater – with semaglutide. The proportions of patients 
achieving the ADA HbA1c target have been reported as 40–49% with albiglutide (30 or 50 
mg); 43–51% with liraglutide (1·2 or 1·8 mg); 62–63% with dulaglutide (0·75 or 1·5 mg); 
and 63% with exenatide extended release (2 mg), compared with 72‒74% with semaglutide 
in this trial.26-29 Similarly, the magnitude of the change from baseline in body weight (–3·7 
to –4·5 kg) is numerically higher than that seen for other GLP-1RAs (reported at –0·4 to –
2·5 kg),26–29 similar to the weight loss reported with semaglutide in an earlier phase 2 dose-
finding study.13 The high proportion of subjects in this trial who achieved the ADA HbA1c 
target of <7·0% without weight gain or hypoglycaemia suggests that semaglutide may 
potentially ameliorate several of the negative health consequences of type 2 diabetes. 
Head-to-head trials comparing semaglutide with other GLP-1RAs are needed to draw firm 
conclusions on potential differences. 
The profile of AEs with semaglutide was similar to that seen with other GLP-1RAs, with GI 
AEs the most frequent.30 These were largely mild-to-moderate and led to treatment 
discontinuation in only a small percentage of subjects; the frequency of nausea peaked 
shortly after treatment initiation and diminished over time. Dose escalation has previously 
been shown to partially ameliorate GI AEs associated with GLP-1RA use,13 as was reflected 
in the trial design. Although lipase and amylase levels increased with semaglutide, there is 
no evidence of an association with pancreatitis, and no episodes of pancreatitis were 
reported in the trial.  
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The modest elevation in pulse rate relative to placebo is also in line with findings for other 
GLP-1RAs, although the decrease in systolic blood pressure also seen with other GLP-1RAs, 
was not statistically significant in this trial.31 In addition, the SUSTAIN 6 trial, designed to 
assess  cardiovascular safety in patients with type 2 diabetes, has demonstrated a 
significant reduction in cardiovascular risk with semaglutide. The first occurrence of 
cardiovascular death, nonfatal myocardial infarction or nonfatal stroke taking place in 6.6% 
of subjects treated with semaglutide 0.5 mg or 1.0 mg and 8.9% with placebo group 
(hazard ratio [HR] 0.74; 95% CI 0.58, 0.95; P<0.001 for noninferiority).32  
In this trial, there was a numerical imbalance in the reporting of neoplasm, although based 
on very low numbers (2 in each of the semaglutide arms versus none in the placebo arm). 
However, in the much larger and longer SUSTAIN 6 trial, malignant neoplasms were equally 
distributed with semaglutide and placebo (HR 0.94; 95% CI 0.67, 1.32), with no apparent 
differences for any types of malignant neoplasms.32 
A limitation of the trial is its short duration, which may not have allowed sufficient time for 
the full effects, on body weight in particular, to be evaluated. Furthermore, this trial had a 
relative small sample size, which carries the risk of not having completely balanced baseline 
characteristics. This was seen for baseline weight and gender distribution. It could be 
speculated that this slightly higher number of heavy males in the 1.0 mg arm could have 
impacted the weight loss results. Results from the remaining phase 3a trials are needed to 
confirm consistency in the results. Another limitation was the frequent use of rescue 
medication, particularly in the placebo arm, which led to missing data in more than 30% of 
placebo subjects. An advantage of this trial design was that use of a volume-matched 
placebo allowed for blinding within each dose for both the clinician and the patient, reducing 
the risk of bias. GLP-1RAs are not generally used as monotherapies but are typically started 
in combination with metformin, which may be another consideration.1   
In conclusion, once-weekly semaglutide monotherapy at a dose of 0·5 mg or 1·0 mg was 
associated with superior glycaemic control and superior reductions in body weight in 
subjects with type 2 diabetes, compared with placebo. AEs were predominantly GI-related 
and the safety and tolerability profile was consistent with previous observations with other 
GLP-1RAs. These findings support a favourable benefit–risk profile of semaglutide in 
patients with type 2 diabetes.  
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Figures 
Figure 1. Participant flow.  
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129 assigned 
semaglutide 0·5 mg
Exposed (n=128)
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119 trial completed
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8 [AE]*a
4 [protocol violation]
5 other
(10 withdrew from trial)
AE, adverse event; GI, gastrointestinal.
*Reflects primary reason for treatment discontinuation, as judged by the investigator; †Subjects did not have an 
HbA1c within the specified range; 
a3 subjects discontinued due to GI AEs and 5 subjects due to other AEs; b3 
subjects discontinued due to GI AEs and 4 subjects due to other AEs; cNo subjects discontinued due to GI AEs and 
3 subjects due to other AEs. 
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Figure 2. Semaglutide 0·5 mg and 1·0 mg once-weekly, compared with placebo, change 
in mean HbA1c by week (A), mean HbA1c after 30 weeks (B), the proportion of subjects 
achieving HbA1c targets of <7·0% (C) and ≤6·5% (D), change in mean body weight by 
week (E), and mean body weight after 30 weeks (F) 
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Table 1. Baseline characteristics. 
 
Semaglutide 0·5 mg Semaglutide 1·0 mg Placebo Total 
     
Age,* years (min–max) 54·6 (30–80) 52·7 (26–80) 53·9 (18–88) 53·7 (18–88) 
HbA1c     
  % (min–max) 8·1 (6·5–10·3) 8·1 (6·4–10·2) 8·0 (6·5–10·2) 8·1 (6·4–10·3) 
  mmol/mol (min–max) 64·9 (47·5–89·1) 65·3 (46·5–88·0) 63·4 (47·5–88·0) 64·5 (46·5–89·1) 
Diabetes duration,* years  
(Min–Max) 
4·9 (0·1–34·5) 3·7 (0·1–28·1) 4·1 (0·1–33·4) 4·2 (0·1–34·5) 
Body weight,* kg (min–max) 89·8 (39·8–174·8) 96·9 (53·7–185·3) 89·1 (42·8–176·7) 91·9 (39·8–185·3) 
BMI,* kg/m2 (min–max) 32·5 (16·4–62·2) 33·9 (18·6–71·8) 32·4 (17·6–56·6) 32·9 (16·4–71·8) 
eGFR (MDRD),*  
mL/min/1·73 m2 (min–max) 
95·9 (35·0–191·0) 100·9 (35·0–195·0) 100·2 (31·0–218·0) 99·0 (31·0–218·0) 
Sex (%)     
  Female 68 (53·1) 50 (38·5) 59 (45·7) 177 (45·7) 
  Male 60 (46·9) 80 (61·5) 70 (54·3) 210 (54·3) 
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Ethnicity (%)     
  Hispanic or Latino 34 (26·6) 45 (34·6) 36 (27·9) 115 (29·7) 
  Not Hispanic or Latino 94 (73·4) 85 (65·4) 93 (72·1) 272 (70·3) 
Race (%)     
  White 83 (64·8) 88 (67·7) 78 (60·5) 249 (64·3) 
  Black or African American 11 (8·6) 11 (8·5) 9 (7·0) 31 (8·0) 
  Asian 26 (20·3) 25 (19·2) 32 (24·8) 83 (21·4) 
* Values are means 
BMI, body-mass index; MDRD, Modification of Diet in Renal Disease 
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Table 2. Study endpoints by treatment group.  
  Semaglutide 
0·5 mg 
  Semaglutide  
1·0 mg 
 Placebo 
 Change 
from 
baseline at 
Week 30 
[SE] 
ETD 
[95% CI] 
p Change 
from 
baseline 
at  
Week 30 
[SE] 
ETD 
[95% CI] 
p Change from 
baseline at 
Week 30 
[SE] 
Glycaemia endpoints 
Mean HbA1c (%) 1·5 
[0·10] 
–1·43 
[-1·71; 1·15] 
<0·0001 1·6 
[0·10] 
–1·53 
[–1·81; –1·25]  
<0·0001 <0·1 
[0·10] 
Mean HbA1c (mmol/mol) 15·9 
[1·08] 
–15·63 
[–18·72; –12·53] 
<0·0001 17·0 
[1·07] 
–16·69 
[–19·77; –13·61] 
<0·0001 0·3 
[1·14] 
Mean FPG (mmol/L) –2·5 
[0·19] 
–1·96 
[–2·49; –1·43] 
<0·0001 –2·3 
[0·18] 
–1·79 
[–2·31; –1·26] 
<0·0001 0·6 
[0·20] 
7-point SMPG (mmol/L)        
   Mean 
 
–2·4 
[0·17] 
–1·68 
[–2·18; –1·18] 
<0·0001 –2·7 
[0·17] 
–1·99 
[–2·48; –1·50] 
<0·0001 –0·7 
[0·18] 
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   Increment –0·8 
[0·16] 
–0·41 
[–0·87; 0·05] 
0·0807 –1·1 
[0·15] 
–0·74 
[–1·19; –0·29] 
0·0014 –0·3 
[0·17] 
Body weight endpoints 
Mean body weight(kg) 3·7 –2·75 
[–3·92; –1·58] 
<0·0001 4·5 –3·56 
[–4·74; –2·38] 
<0·0001 1·0 
Mean BMI (kg/m2) –1·4 
[0·15] 
–0·98 
[–1·40; –0·56] 
<0·0001 –1·6 
[0·14] 
–1·23 
[–1·65; –0·82] 
<0·0001 –0·4 
[0·15] 
Mean waist circumference (cm) –3·7 
[0·55] 
–1·84 
[–3·40; –0·28] 
0·0206 –4·1 
[0·55] 
–2·18 
[–3·74; –0·61] 
0·0066 –1·9 
[0·57] 
Blood pressure and pulse rate 
Mean DBP (mmHg) –0·5 
[0·66] 
–0·89 
[–2·81; 1·02] 
0·36 0·2 
[0·65] 
–0·21 
[–2·12; 1·69] 
0·8 0·4 
[0·71] 
Mean SBP (mmHg) –2·6 
[1·13] 
–0·86 
[–4·15; 2·43] 
 
0·6 –2·7 
[1·12] 
–1·03 
[–4·29; 2·24] 
0·5 –1·7 
[1·23] 
Mean pulse rate (bpm) 2·4 
[0·77] 
2·89 
[0·74; 5·04] 
0·0086 2·4 
[0·77] 
2·97 
[0·83; 5·12] 
0·0068 –0·5 
[0·77] 
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Treatment targets 
  Semaglutide 
0·5 mg 
  Semaglutide  
1·0 mg 
 Placebo 
 Subjects 
achieving 
target 
OR 
[95% CI] 
p Subjects 
achieving 
target 
OR 
[95% CI] 
p Subjects 
achieving 
target 
Proportion achieving HbA1c  
targets, n (%) 
       
   <7·0% (<53 mmol/mol) 95 (74) 16·92 
[8·44; 33·89]            
<0·0001 94 (72) 15·70 
[8·00; 30·83] 
<0·0001  32 (25) 
   ≤6·5% (≤48 mmol/mol) 76 (59) 15·99 
[7·82; 32·68] 
<0·0001 78 (60) 18·34 
[8·96; 37·54] 
<0·0001 17 (13) 
Proportion achieving body weight 
reduction, n (%) 
       
   ≥5% 47 (37) 7·88 
[3·65; 17·04]           
<0·0001 58 (45) 12·01 
[5·53; 26·07]            
<0·0001 9 (7) 
   ≥10% 10 (8) 3·60 
[1·09; 11·95]            
0·0363 17 (13) 6·23 
[1·98; 19·61]            
0·0018 3 (2) 
Proportion achieving HbA1c <7·0% 
without severe or BG–confirmed 
hypoglycaemia and without weight 
gain, n (%) 
85 (66) 12·69 
[6·57; 24·52] 
<0·0001 85 (65) 12·45 
[6·46; 23·99] 
<0·0001 25 (19) 
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BG, blood glucose; BMI, body-mass index; bpm, beats per minute; CI, confidence interval; DBP, diastolic blood pressure; ETD: 
estimated treatment difference vs placebo; FPG, fasting plasma glucose; HBA1c, glycosylated haemoglobin; OR, odds ratio; 
SBP, systolic blood pressure; SD, standard deviation; SE, standard error; SMPG, self-monitored plasma glucose. All p-values 
are two-sided of the null-hypothesis of no treatment difference. 
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Table 3. Adverse events overview. 
 
Semaglutide 0·5 mg Semaglutide 1·0mg Placebo 
N (%) E N (%) E N (%) E 
Number of subjects 128 - - 130 - - 129 - - 
Serious adverse events 7 5.5 10 7 5.4 8 5 3.9 6 
Fatal 0 - - 0 - - 0 - - 
Any adverse events 82 64·1 364 73 56·2 269 69 53·5 224 
Severe 9 7.0 13 8 6.2 12 4 3.1 5 
Moderate 35 27.3 102 31 23.8 80 26 20.2 80 
Mild 71 55.5 249 60 46.2 177 58 45.0 139 
GI adverse events 49 38.3 141 50 38.5 115 19 14.7 42 
Severe 1 0.8 1 2 1.5 2 0 - - 
Moderate 19 14.8 33 17 13.1 35 5 3.9 11 
Mild 38 29.7 107 41 31.5 78 16 12.4 31 
Adverse events leading to premature treatment 
discontinuation 
8    6·3    16 7 5·4 11 3     2·3 5 
   All GI adverse events 5 3·9 7 4 3·1 5 1 0·8 1 
     Nausea 2 1·6 2 2 1·5 2 1 0·8 1 
     Vomiting 1 0·8 1 2 1·5 2 0 - - 
     Diarrhoea 3 2·3 3 0 - - 0 - - 
Adverse events by preferred term (≥5% of 
subjects) 
         
Nausea 26 20·3 44 31 23·8 46 10 7·8 12 
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Diarrhoea 16 12·5 27 14 10·8 19 3 2·3 3 
Headache 15 11·7 43 9 6·9 18 8 6·2 13 
Lipase increased 8 6·3 10 5 3·8 5 5 3·9 5 
Constipation 8 6·3 9 5 3·8 5 1 0·8 2 
Dyspepsia 7 5·5 13 5 3·8 5 3 2·3 3 
Nasopharyngitis 6 4·7 7 6 4·6 9 7 5·4 9 
Vomiting 5 3·9 11 9 6·9 15 2 1·6 2 
Other adverse events          
Pancreatitis  0 - - 0 - - 0 - - 
Cholelithiasis 3 2.3 3* 1 0.8 1 0 - - 
Malignant neoplasms 2 1.6 2 2 1.5 2 0 - - 
Squamous cell carcinoma of the skin 1 0.8 1 0 - - 0 - - 
Breast cell carcinoma 0 - - 1 0.8 1 0 - - 
Breast cancer 1 0.8 1 0 - - 0 - - 
Prostate cancer 0 - - 1 0.8 1 0 - - 
   Benign neoplasms 3 2.3 3 2 1.5 2 0 - - 
E, episodes; GI, gastrointestinal; *1 serious adverse event
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